1. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
- Author
-
Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K, Masiejczyk M, Wróbel A, Dolata I, Kitlińska A, Statkiewicz M, Kuklinska U, Goryca K, Sapała Ł, Grochowska A, Cabaj A, Szajewska-Skuta M, Gabor-Worwa E, Kucwaj K, Białas A, Radzimierski A, Combik M, Woyciechowski J, Mikulski M, Windak R, Ostrowski J, and Brzózka K
- Subjects
- Animals, Antineoplastic Agents chemistry, Cell Line, Tumor, Cyclin-Dependent Kinase 8 chemistry, Disease Models, Animal, Gene Expression Profiling, Gene Expression Regulation, Leukemic drug effects, Humans, Leukemia, Myeloid, Acute genetics, Mice, Models, Molecular, Molecular Conformation, Phosphorylation drug effects, Protein Binding, Protein Kinase Inhibitors chemistry, STAT1 Transcription Factor chemistry, STAT5 Transcription Factor chemistry, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Cyclin-Dependent Kinase 8 antagonists & inhibitors, Leukemia, Myeloid, Acute metabolism, Protein Interaction Domains and Motifs drug effects, Protein Kinase Inhibitors pharmacology, STAT1 Transcription Factor metabolism, STAT5 Transcription Factor metabolism
- Abstract
Inhibition of oncogenic transcriptional programs is a promising therapeutic strategy. A substituted tricyclic benzimidazole, SEL120-34A, is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8), which regulates transcription by associating with the Mediator complex. X-ray crystallography has shown SEL120-34A to be a type I inhibitor forming halogen bonds with the protein's hinge region and hydrophobic complementarities within its front pocket. SEL120-34A inhibits phosphorylation of STAT1 S727 and STAT5 S726 in cancer cells in vitro. Consistently, regulation of STATs- and NUP98-HOXA9- dependent transcription has been observed as a dominant mechanism of action in vivo. Treatment with the compound resulted in a differential efficacy on AML cells with elevated STAT5 S726 levels and stem cell characteristics. In contrast, resistant cells were negative for activated STAT5 and revealed lineage commitment. In vivo efficacy in xenotransplanted AML models correlated with significant repression of STAT5 S726. Favorable pharmacokinetics, confirmed safety and in vivo efficacy provide a rationale for the further clinical development of SEL120-34A as a personalized therapeutic approach in AML.
- Published
- 2017
- Full Text
- View/download PDF